← Leaderboards
Michelle Haber
Roswell Park Cancer Institute Corp
$593,300
Attributed
$1,186,599
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $602.5K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,186,599 · 1
By mechanism
R01$1,186,599 · 1
Top collaborators
- Andrei V Gudkov3 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Elizabeth Bouchard$7,979,280
- Leigh Ellis$3,518,676
Others in their field
Other Rising Stars on “Collaborations”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Gary Mays · Axle Informatics, Llc$65,040,187
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Jeffrey Leintz · National Opinion Research Center$38,969,238
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
Research focus
CollaborationsAntigensAntibodiesAdultAnti-Viral AgentsAtlasesBasic ScienceBiological MarkersCancer DiagnosticsCancer Drug ResistanceCancer TypeCause Of DeathCell LineCellsCentral Nervous SystemCharacteristicsChildChildhood Cancer MortalityChildhood Cancer TreatmentChildhood Solid NeoplasmClinical DataClinically RelevantClinical MaterialDedications
Grant awards (3)
Targeting retrotransposons for improved treatment of refractory childhood cancer$360,013
R01 · FY2025 · CA
Targeting retrotransposons for improved treatment of refractory childhood cancer$224,100
R01 · FY2025 · CA
Targeting retrotransposons for improved treatment of refractory childhood cancer$602,486
R01 · FY2024 · CA